Mulakan
CrashWhen

EBS: It's pretty bad when you underperform TNXP

Panjang
Emergent Biosolutions, Inc. (NYSE:EBS)  
CrashWhen Telah dikemas kini   
NYSE:EBS   Emergent Biosolutions, Inc.
Trend Analysis Fundamental Analysis Beyond Technical Analysis
0
0
trendanalysis fundamental beyondta
Considering TNXP does... well... nothing, EBS underperforming TNXP is disappointing. Still holding and will continue to buy shares if SP falls back into the gray area at $25-$32. Monthly hammer + continuation off a high volume node + 2.618 fib should indicate a trend reversal.
EBS was never a "squeeze" play because it's already worth a billion dollars. Additionally, I don't believe monkey pox is a serious pandemic regardless of what WHO says. EBS still has a pipeline of drugs that generates revenue and profit. With or without Monkey Pox, EBS should see $50-$60 (fibs) imo.
Komen:
Terrible miss on earnings with lowered guidance. More accumulation here.
Penafian

Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.